Efzofitimod demonstrated immune regulatory function improving disease outcomes and mitigating fibrosis in animal models.SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE)…
NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target…
19 subjects enrolled in the OPMD Natural History Study, with multiple subjects entering the eligibility period this year for entry…
-- BROADWAY Phase 3 trial enrollment completed; on-track to report topline data for Phase 3 BROOKLYN and BROADWAY trials in…
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and its collaborator Strategic…
$12.9 Million in Cash and Investments as of September 30, 2023;Runway Expected to Reach Meaningful Development Milestones On Track to…
-- Enrollment ongoing in CHASE Phase 2b clinical trial of KPI-012 for PCED; topline data expected in 2H 2024 ----…
- VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma remains on…
NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating…
WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on…